ASH Conference Coverage
Featured Articles
(Reuters) Dec 9, 2019 - Bluebird bio Inc and Bristol-Myers Squibb Co on Monday reported encouraging initial data from an ongoing early-stage study testing their experimental therapy for multiple myeloma in patients who did not respond to prior treatments. The lowest dose of the therapy, bb21217, had a median duration of response of...
Read Article
(ASH) Dec 10, 2019 - The immunotherapy drug blinatumomab significantly improved survival in children with relapsed B-acute lymphoblastic leukemia (B-ALL) compared with standard chemotherapy in a study presented today during the 61st American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando. Researchers say the...
Read Article
Latest Articles
December 12, 2019
December 10, 2019
December 10, 2019
December 10, 2019
December 10, 2019
December 10, 2019
December 10, 2019
December 10, 2019
View More
News Commentary
There is no ASH Conference Coverage commentary.

OBR Blog
As the ASH Annual Meeting concludes, the late-breaking abstracts are always of great interest. We take a brief look at... Read more
December 04, 2018
As the 2018 American Society of Hematology (ASH) Annual Meeting continues, we focus on two studies that have the... Read more
December 04, 2018

OBR Tweets

Jan 21
William McGivney, PhD: The header for this subject states that while drug/biologic approvals have arrived faster at… https://t.co/YDSG64VXQg

Jan 15
Dean Gesme, MD: C-C Chemokine Receptors (CCR5 or CD195) are ubiquitous on immune cells and play a significant role… https://t.co/FPThNu4aTT

Jan 14
Howard Sandler, MD, MS, FASTRO: Radiotherapy as primary treatment (along with TUR and chemotherapy) is having a bit… https://t.co/pGbHsJJAbs

Jan 14
Tomasz M. Beer, MD: Hot flashes are a common consequence of hormonal therapy for prostate cancer and strategies to… https://t.co/owVbzC4Sex

Jan 13
William McGivney, PhD: In Oncology, drug/biologic development is clearly in a world of orphan diseases. The FDA def… https://t.co/LXXvSjOK2x

Jan 07
H. Jack West, MD: Perhaps a bit surprising for pembro, which has had the luck or efficacy to usually be just a shad… https://t.co/bTjrJlJQwv

Dec 23
Debu Tripathy, MD: Trastuzumab deruxtecan (Enhertu), a HER2-targeting antibody drug conjugate, will represent an im… https://t.co/1x3NMQ6ZkN

Dec 16
Gwen Nichols, MD, @DrGwenNichols of @LLSusa regarding the collaboration between the Leukemia and Lymphoma Society a… https://t.co/mhmBcEyIPo

Dec 16
Andre Goy, MD, @AndreGoyMD of @JTCancerCenter @HackensackUMC regarding the ZUMA-2 study investigating anti-CD19 CAR… https://t.co/3D4ynHF64R

Dec 16
Daniel Pollyea, MD,@DanPollyea of @CUCancerCenter discusses prognostic factors in acute myeloid leukemia (AML) pati… https://t.co/rzlQEK9pie